JonathanEdwardBrammerMD

PubMed

• Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Ca...
  Allison M LeHanka, Ann M Kebede, Neda Amirmokhtari, Joseph R Stanek, Faye Willen
  Pediatric Blood & Cancer. 2025-03-22
• Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.
  Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma
  Journal of Hematology & Oncology. 2025-03-18
• 2 citations
  Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies.
  Jean Caputo, Ayush Peddireddi, Subodh Bhatta, Ying Huang, Evandro Bezerra
  Leukemia & Lymphoma. 2025-01-01

Abstracts/Posters

• Bnz-1, a Selective _-Chain Cytokine Inhibitor Has Clinical Activity in Patients with Cutaneous T Cell Lymphoma By Selectively Blocking IL-2, IL-15 and IL-9 Signaling: ...
  Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
  Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Restoring Functional Deficits in Older Adults with Hematologic Malignancy
  Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
  Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
  Jonathan E. Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
  Jonathan E Brammer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019